Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T15:57:03.581Z.
Calculation as of: 2026-10-06T15:57:03.581Z.
Quote observation: 2026-10-06T15:53:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4b39d0c73cbdfa69f0b7c8f40e573a317b01c7cc2fd28b7d8d8bae27d2fbb310
PEG RATIO
N/A
LENSAR Inc
Market Cap
$82.53M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| LENSAR Inc (LNSR) | $82.53M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $83.48M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.73M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $83.04M | N/A |
| Nutriband Inc. (NTRB)vs › | $81.45M | N/A |
| Pulmonx Corporation (LUNG)vs › | $80.04M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $85.01M | N/A |
| Humacyte, Inc. (HUMA)vs › | $85.13M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $84.78M | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $84.57M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
